0.71
-10.35%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Virax Biolabs Group
Its shares trade under the ticker VRAX. It has been listed since 14 July 2022. In the fiscal year to 31 March 2026, it reported revenue of $12,423 and a net loss of $5.0m. At that date it held total assets of $8.3m and shareholders' equity of $7.6m.
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and medical technology for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 14 Jul 2022
- Employees
- 5
- Website
- viraxbiolabs.com ↗
- Head office
- BIOCITY GLASGOW, LANARKSHIRE, X0, ML1 5UH
- Incorporated in
- E9
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. James FosterChairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder, since 2025$490,692
- Dr. Nigel MccrackenChief Operating Officer, Director, since 2023$491,286
- Mr. Nelson HaightIndependent Director$46,650
- Dr. Iain MillerIndependent Director
- Mr. Evan NortonIndependent Director$46,650
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused product portfolio including ViraxClear and Virax Immune for diagnostics and immunology.
- The company is developing T-Cell Test technology for immunology profiling against viral threats.
- It operates as a holding company with a clear focus on diagnostics and med-tech products.
Weaknesses
- The company has only 5 employees, indicating limited operational capacity.
- The company is a holding company with no specified manufacturing capabilities.
- The company's product development stage is not clearly defined beyond T-Cell Test.
Opportunities
- Growing demand for viral disease diagnostics and immunology solutions in the health care sector.
- Potential expansion of T-Cell Test technology to address multiple viral threats beyond current focus.
- Opportunities to leverage partnerships for distribution and marketing of products.
Threats
- The company's reliance on a single product focus may limit market adaptability.
- Competition in the diagnostics and med-tech industry could impact market share.
- Unverified claims about product effectiveness may lead to regulatory or reputational risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.